For an indolent follicular lymphoma relapse after rituximab‑lenalidomide (R2) failure, is a CD3×CD20 bispecific antibody (e.g., epcoritamab, mosunetuzumab) or chimeric antigen receptor T‑cell therapy (CAR‑T) the more appropriate treatment?

CD3×CD20 Bispecific Antibodies Are the More Appropriate Choice for Indolent Follicular Lymphoma Relapse After R2 Failure

For an indolent follicular lymphoma relapse after rituximab-lenalidomide (R2) failure, CD3×CD20 bispecific antibodies (epcoritamab or mosunetuzumab) should be prioritized over CAR-T cell therapy as the next treatment option. This recommendation is based on the most recent 2025 NCCN Guidelines, which list both modalities as approved options after ≥2 prior systemic therapies, but bispecific antibodies offer distinct practical advantages in the indolent relapse setting 1.

Rationale: Guideline Framework

The 2025 NCCN Guidelines explicitly state that for relapsed/refractory follicular lymphoma after ≥2 prior systemic therapies, both CD3×CD20 bispecific antibodies (mosunetuzumab, epcoritamab) and CD19-directed CAR-T therapies (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) are approved treatment options 1. However, the guidelines do not mandate a specific sequence between these modalities, leaving the decision to clinical judgment.

The 2021 ESMO Guidelines provide additional context: CAR-T therapy in follicular lymphoma "currently remains reserved for transformed FL due to toxicities (registered indication), and its use in indolent lymphoma is limited to clinical trials for refractory disease or relapsing patients with poor prognostic features" 2. This suggests a more cautious approach to CAR-T in purely indolent disease.

Why Bispecific Antibodies First in Indolent Relapse

Efficacy Considerations

Both modalities demonstrate high response rates, but with overlapping confidence intervals:

• Bispecific antibodies show overall response rates of 79-82% with complete response rates of 60-67% 3, 4
• CAR-T therapy demonstrates slightly higher overall response rates of 93% with complete response rates of 75-82% 3, 4

While CAR-T shows numerically superior response rates in meta-analyses 3, 4, the clinical significance of this difference in indolent follicular lymphoma (as opposed to transformed disease) must be weighed against other factors. The 24-month progression-free survival estimates show CAR-T at 62-65% versus bispecific antibodies at 44-54% 5, but these are cross-trial comparisons with overlapping confidence intervals and different patient populations.

Critical Practical Advantages of Bispecific Antibodies

1. Accessibility and Logistics:

• Bispecific antibodies are immediately available as off-the-shelf therapy
• No manufacturing delay (CAR-T requires 2-4 weeks for cell collection and manufacturing)
• No need for bridging chemotherapy while awaiting product
• Outpatient administration is feasible in appropriate settings 6

2. Toxicity Profile:

• Cytokine release syndrome (CRS): Predominantly grade 1-2 with bispecific antibodies, predictable kinetics, manageable with step-up dosing 7, 6
• Neurotoxicity: Grade ≥3 ICANS occurs in 8% with CAR-T versus 0% with bispecific antibodies 4
• Infections: Grade ≥3 infections numerically higher with bispecific antibodies (17% vs 9%), but not statistically significant 4
• Both have similar 1-year non-relapse mortality of 3% 4

3. Preservation of Future Options:

• Using bispecific antibodies first preserves CAR-T as a highly effective salvage option
• CAR-T after bispecific antibody failure remains feasible 8
• The reverse sequence (bispecific after CAR-T failure) has less supporting data

When to Prioritize CAR-T Over Bispecific Antibodies

CAR-T should be considered first-line in specific high-risk scenarios:

1. Proven or suspected histologic transformation to aggressive lymphoma—CAR-T has curative potential based on DLBCL data 8
2. POD24 (progression of disease within 24 months of initial diagnosis) with aggressive clinical features—this identifies patients with poor prognosis who may benefit from the potentially deeper responses of CAR-T 1
3. Younger patients with brief first remissions after rituximab-containing regimens, where high-dose chemotherapy with autologous stem cell transplant or CAR-T may be considered 2

Specific Treatment Algorithm for Your Patient

For indolent FL relapse post-R2:

1. Confirm indolent histology with repeat biopsy to exclude transformation 2

2. If purely indolent grade 1-3a FL:

   • First choice: CD3×CD20 bispecific antibody (epcoritamab or mosunetuzumab)
   • Epcoritamab: subcutaneous, step-up dosing (0.16 mg → 0.8 mg → 48 mg), weekly in cycles 1-3, then every 4 weeks 7
   • Mosunetuzumab: intravenous, step-up dosing, similar schedule 6
   • Monitor for CRS (predominantly cycle 1), manage with tocilizumab if needed
   • Consider hospitalization for first full dose if high tumor burden

3. If transformation suspected or confirmed:

   • First choice: CD19-directed CAR-T therapy
   • Proceed with leukapheresis, bridging therapy if needed, and CAR-T infusion

4. If bispecific antibody fails:

   • CAR-T remains a viable and effective salvage option 8

5. Alternative non-CAR-T/bispecific options (if both are contraindicated):

   • Zanubrutinib + obinutuzumab 1
   • Tafasitamab + lenalidomide + rituximab 1
   • Loncastuximab tesirine + rituximab 1

Common Pitfalls to Avoid

• Do not assume CAR-T is always superior based on response rates alone—consider the patient's disease tempo, comorbidities, and logistical factors
• Do not delay treatment waiting for CAR-T manufacturing if disease is progressing rapidly—bispecific antibodies can be initiated immediately
• Do not underestimate CRS risk with bispecific antibodies in high tumor burden patients—hospitalize for first full dose
• Do not forget to re-biopsy at relapse to exclude transformation, which fundamentally changes the treatment approach 2

Evidence Strength and Nuances

The 2025 NCCN Guidelines 1 represent the most current and authoritative source, listing both modalities as approved options. The 2021 ESMO Guidelines 2 provide additional context suggesting CAR-T should be reserved for more aggressive scenarios in FL. Recent meta-analyses 3, 4 show CAR-T has numerically higher response rates, but these are cross-trial comparisons with significant limitations. The 2024 expert review 8 explicitly states: "we generally favor BsAbs before CAR T as the standard-of-care third-line treatment for the typical patient with R/R FL without concern for aggressive histologic transformation."

The most recent and highest-quality evidence supporting bispecific antibodies in this setting is the 2026 EPCORE FL-1 trial 9, which demonstrated that epcoritamab + R2 achieved 95% overall response rate versus 79% with R2 alone (p<0.0001), with 16-month progression-free survival of 85.5% versus 40.2% (HR 0.21, p<0.0001). While this trial used bispecific antibodies in combination with R2 rather than as monotherapy post-R2 failure, it establishes the high efficacy and manageable safety profile of epcoritamab in the follicular lymphoma population.